Related Experiment Video
Updated: Jun 25, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy
C Y Ho1, H M Lever, R DeSanctis
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115, USA.
Insights
A novel cardiac troponin T (cTnT) mutation, Ser(179)Phe, causes severe familial hypertrophic cardiomyopathy (HCM) in homozygous individuals, leading to sudden death. Heterozygous carriers exhibit a benign clinical course, highlighting the importance of genetic diagnosis in HCM.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
Background:
- Mutations in cardiac troponin T (cTnT) are implicated in ~15% of familial hypertrophic cardiomyopathy (HCM) cases.
- These cTnT mutations often lead to severe HCM with high rates of sudden death and poor prognosis, even with mild hypertrophy.
Purpose of the Study:
- To investigate a family with a history of HCM and sudden deaths in children.
- To identify the genetic basis of severe HCM in this family and understand genotype-phenotype correlations.
Main Methods:
- DNA sequencing of all protein-encoding exons of the cTnT gene.
- Analysis of DNA samples from affected and unaffected family members, including deceased individuals.
- Echocardiographic evaluation of affected individuals.
Main Results:
- A novel mutation, Ser(179)Phe, was identified in exon 11 of the cTnT gene.
- Homozygosity for the Ser(179)Phe mutation was found in a child who died suddenly with severe biventricular hypertrophy.
- Heterozygosity for the Ser(179)Phe mutation was present in unaffected parents and some unaffected children, indicating a benign phenotype.
Conclusions:
- Homozygous Ser(179)Phe mutation in cTnT is causative of a severe, lethal form of HCM with significant morphological abnormalities.
- Heterozygous carriers of the Ser(179)Phe mutation have a benign clinical outcome.
- Genetic testing for cTnT mutations is crucial for diagnosing HCM and predicting clinical outcomes.
Background:
Mutations in the gene that encode cardiac troponin T (cTnT) account for approximately 15% of cases of familial hypertrophic cardiomyopathy (HCM). These mutations are associated with a particularly severe form of HCM characterized by a high incidence of sudden death and a poor overall prognosis, despite subclinical or mild left ventricular hypertrophy.
Methods And Results:
We evaluated a family with HCM and multiple occurrences of sudden death in children. DNA samples were isolated from peripheral blood or paraffin-embedded tissue, and all protein-encoding exons of the cTnT gene were sequenced. A mutation was identified in exon 11 and is predicted to substitute a phenylalanine-for-serine mutation at residue 179 (Ser(179)Phe) in cTnT. Both parents and 3 of 4 surviving and clinically unaffected children were heterozygous for this mutation; another clinically unaffected child did not carry the mutation. Genetic analysis of DNA from a child who died suddenly at age 17 years demonstrated he was homozygous for this mutation. A review of his echocardiogram revealed profound left and right ventricular hypertrophy.
Conclusions:
An homozygous Ser(179)Phe mutation in cTnT causes a severe form of HCM characterized by striking morphological abnormalities and juvenile lethality. In contrast, the natural history of the heterozygous mutation is benign. These studies emphasize the relevance of genetic diagnosis in hypertrophic cardiomyopathy and provide a new perspective on the clinical consequences of troponin T mutations.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Related Concept Videos
Myocarditis I: Introduction
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care